Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer No … ← Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer →